Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Evaluation of long-term efficacy and safety of transdermal fentanyl in thetreatment of chronic noncancer pain
Autore:
Milligan, K; Lanteri-Minet, M; Borchert, K; Helmers, H; Donald, R; Kress, HG; Adriaensen, H; Moulin, D; Jarvimaki, V; Haazen, L;
Indirizzi:
S Cleveland Hosp, Dept Anaesthesia, Middlesbrough TS4 3BW, Cleveland, England S Cleveland Hosp Middlesbrough Cleveland England TS4 3BW eveland, England Janssen Res Fdn, B-2340 Beerse, Belgium Janssen Res Fdn Beerse Belgium B-2340 en Res Fdn, B-2340 Beerse, Belgium Hop Louis Pasteur, Dept Pain Treatment, F-06002 Nice, France Hop Louis Pasteur Nice France F-06002 in Treatment, F-06002 Nice, France Anasthesiol Praxis, Greifswald, Germany Anasthesiol Praxis Greifswald Germany esiol Praxis, Greifswald, Germany Eemland Hosp, Dept Anaesthesiol, Amersfoort, Netherlands Eemland Hosp Amersfoort Netherlands aesthesiol, Amersfoort, Netherlands Strand Private Hosp, Cape Town, South Africa Strand Private Hosp Cape Town South Africa osp, Cape Town, South Africa Univ Vienna, Klin Allgemeine Anasthesie & Intens Med, Abt B, Vienna, Austria Univ Vienna Vienna Austria sthesie & Intens Med, Abt B, Vienna, Austria Univ Ziekenhuis Antwerpen, Edegem, Belgium Univ Ziekenhuis Antwerpen Edegem Belgium uis Antwerpen, Edegem, Belgium Victoria Hosp, Dept Neurol, London, ON N6A 4G5, Canada Victoria Hosp London ON Canada N6A 4G5 Neurol, London, ON N6A 4G5, Canada Oulu Univ, Cent Hosp, Pain Clin, SF-90220 Oulu, Finland Oulu Univ Oulu Finland SF-90220 Hosp, Pain Clin, SF-90220 Oulu, Finland
Titolo Testata:
JOURNAL OF PAIN
fascicolo: 4, volume: 2, anno: 2001,
pagine: 197 - 204
SICI:
1526-5900(200108)2:4<197:EOLEAS>2.0.ZU;2-C
Fonte:
ISI
Lingua:
ENG
Soggetto:
CHRONIC NONMALIGNANT PAIN; CANCER PAIN; ORAL MORPHINE; DOUBLE-BLIND; NEUROPATHIC PAIN; CROSSOVER TRIAL; OPIOIDS; UNDERTREATMENT; THERAPY;
Keywords:
transdermal fentanyl; efficacy; safety; chronic noncancer pain;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
27
Recensione:
Indirizzi per estratti:
Indirizzo: Milligan, K S Cleveland Hosp, Dept Anaesthesia, Marton Rd, Middlesbrough TS4 3BW, Cleveland, England S Cleveland Hosp Marton Rd Middlesbrough Cleveland England TS4 3BW
Citazione:
K. Milligan et al., "Evaluation of long-term efficacy and safety of transdermal fentanyl in thetreatment of chronic noncancer pain", J PAIN, 2(4), 2001, pp. 197-204

Abstract

The objective of this international, multicenter, open-label trial was to assess the efficacy and safety of up to 12 months of therapy with transdermal therapeutic system (TTS) fentanyl in patients (n = 532) with chronic noncancer pain. The trial was completed by 301 (57%) of the patients. The mainoutcome measures were pain control assessment, global treatment satisfaction, patient preference for TTS fentanyl, and quality of life. The mean doseof transdermal fentanyl (TDF) increased from 48 to 90 mug/h during a period of 12 months. During treatment, on average 67% of patients within the efficacy analysis group (n = 524) reported very good, good, or moderate pain control. Global satisfaction (very good or good) was also stable at 42%. Themajority (86%) of patients reported a preference for TDF over their previous treatment (P <.001, binomial test). Short Form 36 quality-of-life scoresimproved from baseline for bodily pain. The most frequent treatment-related adverse events were nausea (31%), constipation (19%), and somnolence (18%). With regard to opioid-specific adverse events (respiratory depression [less than 1%], adrenal insufficiency [less than 1%], drug abuse/dependence [1%], and opioid withdrawal syndrome [3%]), these were extremely rare and, with the exception of opioid withdrawal syndrome, none was considered definitively related to the treatment. Long-term treatment with TDF provided a stable degree of pain control in the majority of patients with moderate to severe chronic noncancer pain. It was preferred by the majority of patients compared with their previous opioid medication. Overall, long-term treatmentwith TDF was generally well tolerated, particularly in view of the low incidence of potentially serious side effects such as drug abuse/dependence and respiratory depression. However, at present, it is important that patients receiving TDF should still be subject to careful assessment and monitoring. (C) 2001 by the American Pain Society.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 18/01/20 alle ore 13:41:04